Disopyramide; Mexiletine; Propafenone/Rifamycins Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
When these two medicines are taken together, your body may not process your heart medicine properly.
What might happen:
The blood level of your heart medicine may decrease and it may not work as well.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. You doctor may want to monitor you more closely while you are taking rifampin, rifabutin or rifapentine with your heart medicine to make sure it is still working for you. The dose of your heart medicine may need to be adjusted after you start or stop rifampin, rifabutin or rifapentine.If you experience a fast or irregular heartbeat, or feel like you might faint, contact your doctor.Your healthcare professionals (e.g. doctor or pharmacist) may already be aware of this drug interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Aitio ML, Mansury L, Tala E, Haataja M, Aitio A. The effect of enzyme induction on the metabolism of disopyramide in man. Br J Clin Pharmacol 1981 Mar;11(3):279-85.
- 2.Staum JM. Enzyme induction: rifampin-disopyramide interaction. DICP 1990 Jul-Aug;24(7-8):701-3.
- 3.Pentikainen PJ, Koivula IH, Hiltunen HA. Effect of rifampicin treatment on the kinetics of mexiletine. Eur J Clin Pharmacol 1982;23(3):261-6.
- 4.Rythmol (propafenone hydrochloride) US prescribing information. Abbott Laboratories March, 2013.
- 5.Dilger K, Hofmann U, Klotz U. Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. Clin Pharmacol Ther 2000 May;67(5):512-20.
- 6.Dilger K, Greiner B, Fromm MF, Hofmann U, Kroemer HK, Eichelbaum M. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. Pharmacogenetics 1999 Oct; 9(5):551-9.
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.